Duchenne muscular dystroph
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC
Almost 1,700 people are diagnosed with bladder cancer in Scotland annually
Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC
The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time
NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree
Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision
Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa
Rare diseases currently affect around 436,000 people living in Scotland
Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma
The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year
Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa
The drug is available in Scotland on the NHS to treat the chronic inflammatory condition
Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatment
The muscle-wasting disorder is estimated to affect one in every 3,500 male births worldwide
MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree
The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide
EC approves Santhera’s Duchenne muscular dystrophy drug Agamree
The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide
Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis
More than 133,520 people in Scotland are affected by the inflammatory condition